These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

342 related items for PubMed ID: 21459937

  • 1. Resolution of inflammation following treatment of ankylosing spondylitis is associated with new bone formation.
    Pedersen SJ, Chiowchanwisawakit P, Lambert RG, Østergaard M, Maksymowych WP.
    J Rheumatol; 2011 Jul; 38(7):1349-54. PubMed ID: 21459937
    [Abstract] [Full Text] [Related]

  • 2. Inflammatory lesions of the spine on magnetic resonance imaging predict the development of new syndesmophytes in ankylosing spondylitis: evidence of a relationship between inflammation and new bone formation.
    Maksymowych WP, Chiowchanwisawakit P, Clare T, Pedersen SJ, Østergaard M, Lambert RG.
    Arthritis Rheum; 2009 Jan; 60(1):93-102. PubMed ID: 19116919
    [Abstract] [Full Text] [Related]

  • 3. Suppression of inflammation and effects on new bone formation in ankylosing spondylitis: evidence for a window of opportunity in disease modification.
    Maksymowych WP, Morency N, Conner-Spady B, Lambert RG.
    Ann Rheum Dis; 2013 Jan; 72(1):23-8. PubMed ID: 22562977
    [Abstract] [Full Text] [Related]

  • 4. Focal fat lesions at vertebral corners on magnetic resonance imaging predict the development of new syndesmophytes in ankylosing spondylitis.
    Chiowchanwisawakit P, Lambert RG, Conner-Spady B, Maksymowych WP.
    Arthritis Rheum; 2011 Aug; 63(8):2215-25. PubMed ID: 21484769
    [Abstract] [Full Text] [Related]

  • 5. The paradoxical effects of TNF inhibitors on bone mineral density and radiographic progression in patients with ankylosing spondylitis.
    Kang KY, Ju JH, Park SH, Kim HY.
    Rheumatology (Oxford); 2013 Apr; 52(4):718-26. PubMed ID: 23275389
    [Abstract] [Full Text] [Related]

  • 6. Continuous long-term anti-TNF therapy does not lead to an increase in the rate of new bone formation over 8 years in patients with ankylosing spondylitis.
    Baraliakos X, Haibel H, Listing J, Sieper J, Braun J.
    Ann Rheum Dis; 2014 Apr; 73(4):710-5. PubMed ID: 23505240
    [Abstract] [Full Text] [Related]

  • 7. [Anti-TNFα therapy in ankylosing spondylitis: symptom control and structural damage modification].
    Andreu JL, Otón T, Sanz J.
    Reumatol Clin; 2011 Apr; 7(1):51-5. PubMed ID: 21794779
    [Abstract] [Full Text] [Related]

  • 8. Costs of tumor necrosis factor blockers per treated patient using real-world drug data in a managed care population.
    Schabert VF, Watson C, Joseph GJ, Iversen P, Burudpakdee C, Harrison DJ.
    J Manag Care Pharm; 2013 Oct; 19(8):621-30. PubMed ID: 24074008
    [Abstract] [Full Text] [Related]

  • 9. Which spinal lesions are associated with new bone formation in patients with ankylosing spondylitis treated with anti-TNF agents? A long-term observational study using MRI and conventional radiography.
    Baraliakos X, Heldmann F, Callhoff J, Listing J, Appelboom T, Brandt J, Van den Bosch F, Breban M, Burmester G, Dougados M, Emery P, Gaston H, Grunke M, Van Der Horst-Bruinsma IE, Landewé R, Leirisalo-Repo M, Sieper J, De Vlam K, Pappas D, Kiltz U, Van Der Heijde D, Braun J.
    Ann Rheum Dis; 2014 Oct; 73(10):1819-25. PubMed ID: 23852807
    [Abstract] [Full Text] [Related]

  • 10. The relationship between inflammation and new bone formation in patients with ankylosing spondylitis.
    Baraliakos X, Listing J, Rudwaleit M, Sieper J, Braun J.
    Arthritis Res Ther; 2008 Oct; 10(5):R104. PubMed ID: 18761747
    [Abstract] [Full Text] [Related]

  • 11. Persistent reduction of spinal inflammation as assessed by magnetic resonance imaging in patients with ankylosing spondylitis after 2 yrs of treatment with the anti-tumour necrosis factor agent infliximab.
    Sieper J, Baraliakos X, Listing J, Brandt J, Haibel H, Rudwaleit M, Braun J.
    Rheumatology (Oxford); 2005 Dec; 44(12):1525-30. PubMed ID: 16091396
    [Abstract] [Full Text] [Related]

  • 12. Clinical and economic burden of extra-articular manifestations in ankylosing spondylitis patients treated with anti-tumor necrosis factor agents.
    Gao X, Wendling D, Botteman MF, Carter JA, Rao S, Cifaldi M.
    J Med Econ; 2012 Dec; 15(6):1054-63. PubMed ID: 22563743
    [Abstract] [Full Text] [Related]

  • 13. MRI vertebral corner inflammation followed by fat deposition is the strongest contributor to the development of new bone at the same vertebral corner: a multilevel longitudinal analysis in patients with ankylosing spondylitis.
    Machado PM, Baraliakos X, van der Heijde D, Braun J, Landewé R.
    Ann Rheum Dis; 2016 Aug; 75(8):1486-93. PubMed ID: 26462728
    [Abstract] [Full Text] [Related]

  • 14. Color and duplex Doppler sonography to detect sacroiliitis and spinal inflammation in ankylosing spondylitis. Can this method reveal response to anti-tumor necrosis factor therapy?
    Unlü E, Pamuk ON, Cakir N.
    J Rheumatol; 2007 Jan; 34(1):110-6. PubMed ID: 17216679
    [Abstract] [Full Text] [Related]

  • 15. Efficacy of antitumor necrosis factor(α) agents on patients with ankylosing spondylitis.
    Ren L, Li J, Luo R, Tang R, Zhu S, Wan L.
    Am J Med Sci; 2013 Dec; 346(6):455-61. PubMed ID: 23715113
    [Abstract] [Full Text] [Related]

  • 16. The formation of autoantibodies and antibodies to TNF-α blocking agents in relation to clinical response in patients with ankylosing spondylitis.
    Arends S, Lebbink HR, Spoorenberg A, Bungener LB, Roozendaal C, van der Veer E, Houtman PM, Griep EN, Limburg PC, Kallenberg CG, Wolbink GJ, Brouwer E.
    Clin Exp Rheumatol; 2010 Dec; 28(5):661-8. PubMed ID: 20822711
    [Abstract] [Full Text] [Related]

  • 17. Responsiveness of the Ankylosing Spondylitis Disease Activity Score (ASDAS) and clinical and MRI measures of disease activity in a 1-year follow-up study of patients with axial spondyloarthritis treated with tumour necrosis factor alpha inhibitors.
    Pedersen SJ, Sørensen IJ, Hermann KG, Madsen OR, Tvede N, Hansen MS, Thamsborg G, Andersen LS, Majgaard O, Loft AG, Erlendsson J, Asmussen K, Johansen JS, Jurik AG, Møller J, Hasselquist M, Mikkelsen D, Skjødt T, Hansen A, Ostergaard M.
    Ann Rheum Dis; 2010 Jun; 69(6):1065-71. PubMed ID: 19740906
    [Abstract] [Full Text] [Related]

  • 18. The change of bone mineral density according to treatment agents in patients with ankylosing spondylitis.
    Kang KY, Lee KY, Kwok SK, Ju JH, Park KS, Hong YS, Kim HY, Park SH.
    Joint Bone Spine; 2011 Mar; 78(2):188-93. PubMed ID: 20621536
    [Abstract] [Full Text] [Related]

  • 19. Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor alpha agents.
    Braun J, Baraliakos X, Listing J, Davis J, van der Heijde D, Haibel H, Rudwaleit M, Sieper J.
    Arthritis Rheum; 2007 May 15; 57(4):639-47. PubMed ID: 17471540
    [Abstract] [Full Text] [Related]

  • 20. Increase in bone density in patients with spondyloarthritis during anti-tumor necrosis factor therapy: 6-year followup study.
    Durnez A, Paternotte S, Fechtenbaum J, Landewé RB, Dougados M, Roux C, Briot K.
    J Rheumatol; 2013 Oct 15; 40(10):1712-8. PubMed ID: 23950191
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.